This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019, developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of the anti-severe acute respiratory syndrome coronavirus 2 neutralizing antibody pemivibart as pre-exposure prophylaxis. The recommendation is based on evidence derived from a systematic review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Information on pemivibart is included in the U.S. Food and Drug Administration Emergency Use Authorization for this agent.

中文翻译：

---

美国传染病学会关于 COVID-19 管理的 2024 年临床实践指南更新：用于暴露前预防的抗 SARS-CoV-2 中和抗体 Pemivibart。


本文重点更新了美国传染病学会制定的 2019 冠状病毒病患者治疗和管理临床实践指南。指南小组提出了使用抗严重急性呼吸系统综合症冠状病毒 2 中和抗体 pemivibart 作为暴露前预防的建议。该建议基于来自系统评价的证据，并遵循根据 GRADE（建议分级、评估、开发和评估）方法对证据质量和建议强度进行评级的标准化方法。有关培米巴的信息包含在美国食品和药物管理局对该药物的紧急使用授权中。